Lymphopenia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023

リンパ球減少症治療法の世界市場予測・分析2019-2023

◆タイトル:Lymphopenia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32129
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年10月31日
◆ページ数:155
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社の本調査レポートでは、リンパ球減少症治療法の世界市場について調べ、リンパ球減少症治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、リンパ球減少症治療法の市場規模をセグメンテーション別(製品別(後天性リンパ球減少症、遺伝性リンパ球減少症)、)と地域別(グローバル)に分けて算出しました。Technavio社はリンパ球減少症治療法の世界市場規模が2019-2023期間中に年平均4%成長すると予測しています。
・サマリー
・レポートの範囲
・リンパ球減少症治療法の市場状況
・リンパ球減少症治療法の市場規模
・リンパ球減少症治療法の市場予測
・リンパ球減少症治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(後天性リンパ球減少症、遺伝性リンパ球減少症)
・リンパ球減少症治療法の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...

Global Lymphopenia Therapeutics Market: About this market
Technavio’s lymphopenia therapeutics market analysis considers sales from acquired lymphopenia and inherited lymphopenia product segments. Our analysis also considers the sales of lymphopenia therapeutics in Asia, Europe, North America, and ROW. In 2018, the acquired lymphopenia segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising incidence of diseases from various therapy areas such as blood cancer and autoimmune disorders will play a significant role in the acquired lymphopenia segment to maintain its market position. Also, our global lymphopenia therapeutics market report looks at factors such as increasing risk factors for lymphopenia. However, adverse effects associated with therapeutics, high cost of therapeutics, and stringent regulations may hamper the growth of the lymphopenia therapeutics industry over the forecast period.

Global Lymphopenia Therapeutics Market: Overview
Increasing risk factors for lymphopenia
High prevalence of risk factors such as inherited diseases, autoimmune disorders, blood cancer or blood diseases, and infectious diseases such as AIDS has led to the reduction in lymphocyte counts in blood of a patient. This increases the incidence of lymphopenia. Pharmaceutical companies are investing in research and development activities to come up with effective and cost-efficient therapeutic drugs for lymphopenia. The availability of these drugs will lead to the expansion of the global lymphopenia therapeutics market at a CAGR of almost 4% during the forecast period.

Strategic alliances
Vendors are focusing on addressing the issues associated with high cost of research and development activities of therapeutic drugs by collaborating with pharmaceutical companies. They are also expanding their distribution networks by entering strategic alliances with other vendors. As a result, the development and commercialization of advanced therapies and drugs for lymphopenia is increasing. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global lymphopenia therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global lymphopenia therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lymphopenia therapeutics manufacturers, that include AbbVie Inc., Bristol-Myers Squibb Co., CSL Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Grifols SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, and Sanofi.
Also, the lymphopenia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Acquired lymphopenia – Market size and forecast 2018-2023
• Inherited lymphopenia – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
• Increasing research in regenerative medicines
• Strategic alliances
• Presence of patient assistance programs
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Bristol-Myers Squibb Co.
• CSL Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Grifols SA
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Novartis AG
• Sanofi
PART 13: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors


Exhibit 01: Years in consideration
Exhibit 02:
Exhibit 03: Global pharmaceuticals market
Exhibit 04: Segments of global pharmaceuticals market
Exhibit 05: Market characteristics
Exhibit 06: Market characteristics analysis
Exhibit 07: Market segments
Exhibit 08: Market definition – Inclusions and exclusions checklist
Exhibit 09: Market size 2018
Exhibit 10: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 11: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 12: Five forces analysis 2018
Exhibit 13: Five forces analysis 2023
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition – Five forces 2018
Exhibit 20: Product – Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: Acquired lymphopenia – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Acquired lymphopenia – Year-over-year growth 2019-2023 (%)
Exhibit 24: Inherited lymphopenia – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Inherited lymphopenia – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Customer landscape analysis
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Decision framework
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendor landscape analysis
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AbbVie Inc. – Vendor overview
Exhibit 54: AbbVie Inc. – Business segments
Exhibit 55: AbbVie Inc. – Organizational developments
Exhibit 56: AbbVie Inc. – Geographic focus
Exhibit 57: AbbVie Inc. – Key offerings
Exhibit 58: AbbVie Inc. – Key customers
Exhibit 59: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 60: Bristol-Myers Squibb Co. – Business segments
Exhibit 61: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 62: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 63: Bristol-Myers Squibb Co. – Key offerings
Exhibit 64: Bristol-Myers Squibb Co. – Key customers
Exhibit 65: CSL Ltd. – Vendor overview
Exhibit 66: CSL Ltd. – Business segments
Exhibit 67: CSL Ltd. – Organizational developments
Exhibit 68: CSL Ltd. – Geographic focus
Exhibit 69: CSL Ltd. – Segment focus
Exhibit 70: CSL Ltd. – Key offerings
Exhibit 71: CSL Ltd. – Key customers
Exhibit 72: Gilead Sciences Inc. – Vendor overview
Exhibit 73: Gilead Sciences Inc. – Business segments
Exhibit 74: Gilead Sciences Inc. – Organizational developments
Exhibit 75: Gilead Sciences Inc. – Geographic focus
Exhibit 76: Gilead Sciences Inc. – Key offerings
Exhibit 77: Gilead Sciences Inc. – Key customers
Exhibit 78: GlaxoSmithKline Plc – Vendor overview
Exhibit 79: GlaxoSmithKline Plc – Business segments
Exhibit 80: GlaxoSmithKline Plc – Organizational developments
Exhibit 81: GlaxoSmithKline Plc – Geographic focus
Exhibit 82: GlaxoSmithKline Plc – Segment focus
Exhibit 83: GlaxoSmithKline Plc – Key offerings
Exhibit 84: GlaxoSmithKline Plc – Key customers
Exhibit 85: Grifols SA – Vendor overview7
Exhibit 86: Grifols SA – Business segments7
Exhibit 87: Grifols SA – Organizational developments
Exhibit 88: Grifols SA – Geographic focus
Exhibit 89: Grifols SA – Segment focus
Exhibit 90: Grifols SA – Key offerings
Exhibit 91: Grifols SA – Key customers
Exhibit 92: Johnson & Johnson Services Inc. – Vendor overview
Exhibit 93: Johnson & Johnson Services Inc. – Business segments
Exhibit 94: Johnson & Johnson Services Inc. – Organizational developments
Exhibit 95: Johnson & Johnson Services Inc. – Geographic focus
Exhibit 96: Johnson & Johnson Services Inc. – Segment focus
Exhibit 97: Johnson & Johnson Services Inc. – Key offerings
Exhibit 98: Johnson & Johnson Services Inc. – Key customers
Exhibit 99: Merck & Co. Inc. – Vendor overview
Exhibit 100: Merck & Co. Inc. – Business segments
Exhibit 101: Merck & Co. Inc. – Organizational developments
Exhibit 102: Merck & Co. Inc. – Geographic focus
Exhibit 103: Merck & Co. Inc. – Segment focus
Exhibit 104: Merck & Co. Inc. – Key offerings
Exhibit 105: Merck & Co. Inc. – Key customers
Exhibit 106: Novartis AG – Vendor overview
Exhibit 107: Novartis AG – Business segments
Exhibit 108: Novartis AG – Organizational developments
Exhibit 109: Novartis AG – Geographic focus
Exhibit 110: Novartis AG – Segment focus
Exhibit 111: Novartis AG – Key offerings
Exhibit 112: Novartis AG – Key customers
Exhibit 113: Sanofi – Vendor overview
Exhibit 114: Sanofi – Business segments
Exhibit 115: Sanofi – Organizational developments
Exhibit 116: Sanofi – Geographic focus
Exhibit 117: Sanofi – Segment focus
Exhibit 118: Sanofi – Key offerings
Exhibit 119: Sanofi – Key customers
Exhibit 120: Validation techniques employed for market sizing
Exhibit 121: List of abbreviations
Exhibit 122: Definition of market positioning of vendors



【掲載企業】

AbbVie Inc., Bristol-Myers Squibb Co., CSL Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Grifols SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, and Sanofi.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[リンパ球減少症治療法の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆